Beta Bionics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
Beta Bionics (BBNX) priced an underwritten public offering of 7,652,175 common shares at $17.25 and pre-funded warrants for 1,043,484 shares at $17.2499 per warrant, expected to raise gross proceeds of $150.0 million before fees.
Rhea-AI Summary
Beta Bionics (BBNX) priced an underwritten public offering of 7,652,175 common shares at $17.25 and pre-funded warrants for 1,043,484 shares at $17.2499 per warrant, expected to raise gross proceeds of $150.0 million before fees. The offering is expected to close on or about September 17, 2026, subject to customary conditions, and underwriters have a 30-day option to buy up to 1,304,348 additional common shares at the public offering price, less discounts and commissions.
Beta Bionics expects to use net proceeds for general corporate purposes, including commercialization of Mint, manufacturing expansion, R&D and clinical development, product enhancements, potential strategic opportunities, and working capital and operating expenses. J.P. Morgan, Piper Sandler, Wells Fargo Securities and Leerink Partners are joint book-running managers, and the securities are being issued under an effective Form S-3 shelf registration.
Positive
- Gross proceeds of $150.0 million expected from the offering before fees
- Use of proceeds includes Mint commercialization and manufacturing expansion
Negative
- Offering includes 7,652,175 new shares plus a 1,304,348-share underwriter option, implying dilution
- Pre-funded warrants for 1,043,484 shares add potential future share overhang
News Explained
The priced financing is not yet closed; its $150 million gross size equals 933.5 days of second-quarter operating cash use, before fees.
On
The company is offering 7,652,175 common shares and pre-funded warrants for 1,043,484 shares; if the warrant shares become outstanding, the added shares would increase the total count and reduce existing holders’ percentage ownership absent offsetting changes.
As an underwritten offering, an investment bank buys securities from the issuer for resale, and the disclosed
On the last reported second-quarter operating-cash-use basis, the gross offering equals 933.5 days of the last reported operating cash use.
On that same basis, the offering is below reported total cash and investments: 933.5 days versus 1,401.1 days. The closing and the final prospectus supplement are the key checkpoints for completion and the final terms, including fees.
Sources and calculations
- Beta Bionics pricing announcement (2026-09-15)
- Dilution definition (2026-07-17)
- Pre-funded warrant definition (2026-07-17)
- Underwritten offering definition (2026-07-17)
- Prospectus supplement purpose (2026-07-17)
- Beta Bionics second-quarter 2026 fundamentals (2026-06-30)
- Offering gross against the last reported quarterly operating outflow, in days at that rate $150,000,000 / ($14,622,000 / 91) = 933.5 days
- Available liquidity against the last reported quarterly operating outflow, in days at that rate ($44,318,000 + $136,171,000 + $44,648,000) / ($14,622,000 / 91) = 1401.1 days
Key Figures
- Common shares offered
- 7,652,175 shares
- Public offering
- Public offering price
- $17.25 per share
- Common stock
- Pre-funded warrants
- 1,043,484 shares
- Purchase price of $17.2499 per share; exercise price of $0.0001
- Gross proceeds
- $150.0 million
- Before underwriting discounts, commissions and offering expenses
- Expected closing
- September 17, 2026
- Subject to customary closing conditions
- Underwriter option
- 1,304,348 additional shares
- 30-day option at the public offering price less underwriting discounts and commissions
Historical Context
-
Mint received FDA clearance, with Q1 2027 launch and 1.5 million-unit 2027 capacity.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
pre-funded warrants financial
shelf registration statement regulatory
form s-3 regulatory
underwritten public offering financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
IRVINE, Calif., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX) today announced the pricing of an underwritten public offering of 7,652,175 shares of its common stock at a price to the public of
Beta Bionics expects to use the net proceeds from this offering for general corporate purposes, which may include costs associated with the commercialization of MintTM, including expansion of Beta Bionics’ manufacturing facilities, research and development and clinical development, investment in product enhancements, potential strategic opportunities and working capital and operating expenses.
J.P. Morgan, Piper Sandler, Wells Fargo Securities and Leerink Partners are acting as the joint book-running managers for the offering.
The shares of common stock and pre-funded warrants described above are being offered by Beta Bionics pursuant to a shelf registration statement on Form S-3 that was filed by Beta Bionics with the Securities and Exchange Commission (SEC) on February 24, 2026 and automatically became effective upon filing. A final prospectus supplement related to the offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus related to this offering, when available, may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; or from Piper Sandler & Co., 350 North 5th Street, Suite 1000, Minneapolis, Minnesota 55401, Attention: Prospectus Department, by telephone at (800) 747-3924, or by email at prospectus@psc.com; or from Wells Fargo Securities, LLC, Attention: Wells Fargo Securities, 90 South 7th Street, 5th Floor, Minneapolis, Minnesota 55402, by telephone at 800-645-3751 (option #5), by email at WFScustomerservice@wellsfargo.com; or from Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, Massachusetts 02109, by telephone at (800) 808-7525, ext. 6105, or by email at syndicate@leerink.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Beta Bionics
Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development, and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing advanced adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The iLet Bionic Pancreas is the first FDA-cleared insulin delivery device that autonomously determines every insulin dose and offers the potential to substantially improve overall outcomes across broad populations of PWD.
Cautionary Note on Forward-Looking Statements
Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. These statements may be identified by introductory words such as “may,” “expects,” “goal,” “intend," "will," "would,” “subject to” or words of similar meaning, or by the fact that they do not relate strictly to historical or current facts. Such forward-looking statements include statements regarding Beta Bionics’ expectations with respect to the completion, timing and size of the public offering, and the use of proceeds from the offering. For such statements, Beta Bionics claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Beta Bionics’ expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, changes in market conditions, the risk that the offering will not be consummated on the timing contemplated or otherwise, and the satisfaction of customary closing conditions related to the offering, as well as the risks and uncertainties discussed in the preliminary prospectus supplement for the offering and other risks and uncertainties disclosed in Beta Bionics’ filings with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 24, 2026, as updated by its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the SEC on July 29, 2026, and other filings that Beta Bionics may make from time to time with the SEC. These forward-looking statements represent Beta Bionics’ judgment as of the time of this release. Beta Bionics disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.
Investor Relations:
Blake Beber
Head of Investor Relations
ir@betabionics.com
Media and Public Relations:
Felicia Sanborn
Vice President of Marketing
media@betabionics.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many securities is Beta Bionics offering and at what prices?
Beta Bionics is offering 7,652,175 shares of common stock at a public offering price of $17.25 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,043,484 shares of common stock at a purchase price of $17.2499 per warrant, with an exercise price of $0.0001 per share.
What additional purchase option have the underwriters received?
The underwriters have a 30-day option to purchase up to 1,304,348 additional shares of Beta Bionics common stock at the public offering price, less underwriting discounts and commissions.
When is the Beta Bionics offering expected to close?
The offering is expected to close on or about September 17, 2026, subject to customary closing conditions.
What are the planned uses of net proceeds from the offering?
Beta Bionics expects to use net proceeds for general corporate purposes, which may include costs associated with commercialization of Mint, expansion of manufacturing facilities, research and development and clinical development, investment in product enhancements, potential strategic opportunities, and working capital and operating expenses.
Under what registration is this offering being conducted?
The shares of common stock and pre-funded warrants are being offered under a shelf registration statement on Form S-3 filed with the SEC on February 24, 2026, which became effective upon filing.
How can investors obtain the final prospectus supplement for the offering?
A final prospectus supplement will be filed with the SEC and made available at http://www.sec.gov. Copies, when available, may also be requested from J.P. Morgan Securities, Piper Sandler, Wells Fargo Securities, or Leerink Partners using the postal addresses, telephone numbers, or email contacts provided in the announcement.